

Anti-CD55 (Extracellular region) Antibody
Catalog # AN1697**Specification**

Anti-CD55 (Extracellular region) Antibody - Product Information

| | |
|-------------------|------------------------|
| Application | WB, IHC |
| Primary Accession | P08174 |
| Host | Mouse |
| Clonality | Mouse Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 41400 |

Anti-CD55 (Extracellular region) Antibody - Additional Information

| | |
|-----------------------------------------------------------------|------|
| Gene ID | 1604 |
| Other Names | |
| Complement decay-accelerating factor, DAF, CD_antigen, CD55, CR | |

Target/Specificity

CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2 α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.

Dilution

WB~~1:1000
IHC~~1:100~500

Format

Protein G Purified

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Anti-CD55 (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Shipping


Blue Ice

Anti-CD55 (Extracellular region) Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-CD55 (Extracellular region) Antibody - Images



Immunocytochemical labeling of CD55 in paraformaldehyde fixed human MDA-MB-231 breast cancer cells. The cells were labeled with mouse monoclonal anti-CD55 (CM0331). The antibody was detected using goat anti-mouse DyLight® 594.



Representative Standard Curve using mouse monoclonal anti-CD55 (CM0331) for ELISA capture of human recombinant CD55 extracellular region with His-tag. Capture was detected by using an anti-His-tag antibody followed by appropriate secondary antibody conjugated to HRP.

Anti-CD55 (Extracellular region) Antibody - Background

CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in

tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2 α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.